Drug Profile
GW 353430
Alternative Names: Anti-CD23 monoclonal antibody - GSKLatest Information Update: 02 Aug 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class Antirheumatics; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Asthma; Rheumatic disorders
Most Recent Events
- 22 Jan 2001 Glaxo Wellcome has merged with SmithKline Beecham to form GlaxoSmithKline
- 01 Mar 1999 Profile reviewed
- 26 Mar 1998 Preclinical development for Asthma in United Kingdom (Unknown route)